-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Friday, NeuroSense Therapeutics Receives Dual Nasdaq Non-Compliance Notices For Minimum Bid Price And $35M Market Value Requirements, Given Until September 29, 2026

Benzinga·04/06/2026 07:19:05
Listen to the news
  • Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq
  • Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements
  • The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value